Response
Kario et al emphasized the significance of acquired activated protein C (APC) resistance in arterial diseases and established some links to other coagulation abnormalities. This issue is relevant to a better understanding of thrombotic disorders and deserves further comment.
In the Bruneck study, 1 insensitivity to APC not caused by the Leiden mutation emerged as a strong risk predictor of advanced atherosclerosis and arterial disease. This finding was not unexpected given the well-established association between APC resistance and arterial/venous thrombosis in nonwhite populations in which factor V mutations are particularly rare or even absent. 2 Until recently, however, the condition of factor V mutation-independent APC resistance has attracted only minor attention in clinical research. In 1998, Sampram and colleagues 3 were the first to report an increased risk of peripheral artery disease in patients with APC resistance but no gene mutation. The Bruneck study 1 extended these findings to other types of vascular disease and atherosclerosis in general. In the past months, the issue was also settled for venous thrombosis. Two large surveys 4, 5 consistently observed an increased risk of venous thromboembolism among subjects with APC resistance but no factor V Leiden. In the Bruneck cohort, 57 subjects experienced venous thrombosis. APC resistance with and without the factor V mutation was observed in 9% of patients each, and both conditions afforded an increased risk of disease status (OR 3.8 and 3.3, PϽ0.05).
Prevalence of phenotypic APC resistance without detectable gene mutation was underestimated from previous case-control studies. In the Bruneck study, 1 which is representative of the general community in central Europe, this condition was at least as frequent as the Leiden mutation itself. In the population-based Vicenza Thrombophilia Project, the factor V mutation and n-APC ratios Յ0.84, which conferred a significantly increased thrombosis risk, occurred at a ratio of 1:4. 5 All studies in concert provide substantial evidence of a prominent role of an inadequate protein C pathway in all kinds of thrombotic diseases. The factor V mutation is only one facet of this association. We agree with Kario et al that the time has come to recommend the use of functional APC assays in the risk evaluation of subjects with venous/arterial thrombosis. When doing so, one should be aware of the potential influences that the acute phase reaction evoked by severe illness and infections can have on APC ratios and, if applicable, consider remeasurement at a later date for the purpose of confirmation. 
